Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Stickleback fish have repeatedly moved between marine and freshwater environments, with widespread convergent evolution to adapt and readapt to these environments in different species. Flying fish can fly up to 400 m (1,300 ft) at speeds of more than 70 kilometres per hour (43 mph) at a maximum altitude of more than 6 m (20 ft), much like other flying birds, bats and other gliders. Extinct fish of the family Thoracopteridae, like Thoracopterus or Potanichthys, were similar to modern flying fish (gliding ability thanks to enlarged pair of pectoral fins and a deeply forked tail fin) which is not, however, considered to be their descendant. The cleaner wrasse Labroides dimidiatus of the Indian Ocean is a small, longitudinally-striped black and bright blue cleaner fish, just like the cleaner goby Elacatinus evelynae of the western Atlantic. The fish of the now discredited genus Stylophthalmus are only distantly related, but their larvae (Stomiiformes and Myctophiformes) have developed similar, stalked eyes. (see: Stylophthalmine trait) Sawfish (a group of rays related to guitarfish), unrelated sawsharks (a group of sharks), and the extinct sawskates (another group of rays related to modern skates) all convergently evolved a saw-like rostrum with sharp transverse teeth for hunting. This evolutionary process has been named "pristification". Underwater camouflage is found independently in many fish like: leafy seadragon (large part of its body is just for camouflage), pygmy seahorse, leaf scorpionfish, flounder, peacock flounder.
=== December === 1 December – NHS Grampian suspends visiting at Dr Gray's Hospital in Elgin following an outbreak of vomiting and diarrhoea. 3 December – A teenage boy is sentenced to life imprisonment with a minimum of 18 years for the murder of Danielle Davidson, who was stabbed with a Rambo-style knife following an argument over a e-scooter in Edinburgh in May 2023. A report by Audit Scotland says that fundamental changes are required in the way NHS Scotland provides services are "urgently needed" and that "difficult decisions" about whether some services can continue to be provided may need to be taken. 4 December – Finance Secretary Shona Robison delivers the 2024 budget, which includes planned changes to taxation and a pledge to scrap the two child benefit cap in Scotland. Rocket manufacturer Orbex announces plans to pause the construction of a spaceport in Sutherland in order to focus on the construction of its SaxaVord Spaceport site in Shetland. 6 December – First Minister John Swinney and Prime Minister Keir Starmer hold private talks about the Scottish Government's plans to scrap the two child benefit cap, which are later described as "helpful". A single case of bovine spongiform encephalopathy (BSE) has been identified on a farm in Dumfries and Galloway, authorities confirm. Professor Iain Gillespie resigns as principal of Dundee University following controversy over a £7,000 business trip he and a colleague took to Hong Kong. 7 December – Storm Darragh: An amber warning for high winds, and yellow warnings for wind and rain, are in place in Scotland.
LGD-4033, also known by the developmental code name VK5211 and by the black-market name Ligandrol, is a selective androgen receptor modulator (SARM) which is under development for the treatment of muscle atrophy in people with hip fracture. It was also under development for the treatment of cachexia, hypogonadism, and osteoporosis, but development for these indications was discontinued. LGD-4033 has been reported to dose-dependently improve lean body mass and muscle strength in preliminary clinical trials, but is still being developed and has not been approved for medical use. The drug is taken by mouth. Known possible side effects of LGD-4033 include headache, dry mouth, adverse lipid changes like decreased high-density lipoprotein (HDL) cholesterol levels, changes in sex hormone concentrations like decreased testosterone levels, elevated liver enzymes, and liver toxicity. The potential of LGD-4033 and other SARMs for producing masculinization is largely uncharacterized and hence is unknown. LGD-4033 is a nonsteroidal SARM, acting as an agonist of the androgen receptor (AR), the biological target of androgens and anabolic steroids like testosterone and dihydrotestosterone (DHT). However, it shows dissociation of effect between tissues in preclinical studies, with agonistic and anabolic effects in muscle and bone and partially agonistic or antagonistic effects in the prostate gland. LGD-4033 was first described in 2010. It is less clinically studied than other SARMs like enobosarm, with only a few small clinical trials having been conducted and reported.
MG132 is a potent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). It belongs to the class of synthetic peptide aldehydes. It reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable strains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. MG132 activates c-Jun N-terminal kinase (JNK1), which initiates apoptosis. MG132 also inhibits NF-κB activation with an IC50 of 3 μM and prevents β-secretase cleavage.
== Treatment == Currently, there are no treatments for any of the congenital myopathies. Depending on the severity, there are different therapies available to help alleviate any pain and aid patients in performing varying activities. For example, many congenital myopathy patients are involved in physical or occupational therapy in an attempt to strengthen their skeletal muscles. Orthopedic surgery is usually necessary to correct skeletal deformities secondary to muscle weakness, such as scoliosis. Survival is typically determined by the level of respiratory muscle insufficiency.
Sources: en.wikipedia.org
In AMS v Union locale des syndicats CGT a French trade union claimed that the French Labour Code should not exclude casual workers from counting toward the right to set up a work council that an employing entity must inform and consult. They said this contravened the Information and Consultation of Employees Directive and also CFREU article 27. The Court of Justice agreed that the French Labour Code was incompatible with the Directive, but held that article 27 was expressed too generally to create direct rights. On this view, legislation was necessary to make abstract human rights principles concrete, and legally enforceable. Beyond human rights, the Court of Justice has recognised at least five further 'general principles' of EU law. The categories of general principles are not closed, and may develop according to the social expectations of people living in Europe.
==== Enchondroma ==== Enchondromas are benign tumors of hyaline cartilage. Within a bone, enchondromas are often found in metaphyses. They can be found in many types of bone, including small bones, long bones, and the axial skeleton. X-ray of enchondromas shows well-defined borders and a stippled appearance. Presentation of multiple enchondromas is consistent with multiple enchondromatosis (Ollier Disease). Treatment of enchondromas involves surgical curettage and grafting.
=== Urban soils === The British Geological Survey reported the amount and distribution of PAH compounds including parent and alkylated forms in urban soils at 76 locations in Greater London. The study showed that parent (16 PAH) content ranged from 4 to 67 mg/kg (dry soil weight) and an average PAH concentration of 18 mg/kg (dry soil weight) whereas the total PAH content (33 PAH) ranged from 6 to 88 mg/kg and fluoranthene and pyrene were generally the most abundant PAHs. Benzo[a]pyrene (BaP), the most toxic of the parent PAHs, is widely considered a key marker PAH for environmental assessments; the normal background concentration of BaP in the London urban sites was 6.9 mg/kg (dry soil weight). London soils contained more stable four- to six-ringed PAHs which were indicative of combustion and pyrolytic sources, such as coal and oil burning and traffic-sourced particulates. However, the overall distribution also suggested that the PAHs in London soils had undergone weathering and been modified by a variety of pre-and post-depositional processes such as volatilization and microbial biodegradation.
=== Advanced tools === By around 200,000 BP, Middle Paleolithic stone tool manufacturing spawned a tool-making technique known as the prepared-core technique, which was more elaborate than previous Acheulean techniques. This technique increased efficiency by allowing the creation of more controlled and consistent flakes. It allowed Middle Paleolithic humans to create stone-tipped spears, which were the earliest composite tools, by hafting sharp pointy stone flakes onto wooden shafts. In addition to improving tool-making methods, the Middle Paleolithic also saw an improvement of the tools themselves that allowed access to a wider variety and amount of food sources. For example, microliths or small stone tools or points were invented around 70,000–65,000 BP and were essential to the invention of bows and atlatls (spear throwers) in the following Upper Paleolithic. Harpoons were invented and used for the first time during the late Middle Paleolithic (c. 90,000 BP); the invention of these devices brought fish into the human diets, which provided a hedge against starvation and a more abundant food supply. Thanks to their technology and their advanced social structures, Paleolithic groups such as the Neanderthals—who had a Middle Paleolithic level of technology—appear to have hunted large game just as well as Upper Paleolithic modern humans, and the Neanderthals in particular may have likewise hunted with projectile weapons.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.